Speculation and Illusions

The fund’s increased holding represents 5.96% of its reported assets under management. As of December 31, 2025, the total value of the Spyre Therapeutics stake was $120.74 million. These figures, however, are less illuminating than the fact that a significant portion of a fund’s capital is tied to a company that, as we shall see, exists primarily in the realm of future possibilities.








